Articles

Yeti’s stock was having its best day in a year on Thursday, after the outdoor-products maker reported second-quarter earnings that rose above expectations, boosted by record cooler sales.

Board of Texas real-estate company confirms offer from billionaire’s Pershing Square hedge fund

Revenue remains about flat at $184 million

One analyst notes “a legitimate uplift in demand for fiber infrastructure to support the growth in AI” — but short covering is likely also at play with shares up 500% in a month.

Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.

No banking or credit card information was included in the theft

The number of Americans who applied for unemployment benefits last week fell sharply to 233,000 and receded from a nearly one-year, suggesting layoffs remain quite low and that the labor market is still in good shape.

Selloff creates cast-offs to jump on.

The company’s stock climbed 6% in premarket trading.

Merck & Co. said Thursday it’s discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events.

Under Armour Inc.’s stock rose 7.7% premarket Thursday after the athletic-apparel maker beat Wall Street’s top and bottom-line expectations in its first-quarter results and raised its earnings outlook.

The company is gearing up for the rollout of its doughnuts at McDonald’s restaurants, starting in the Midwest with Chicago.